Bidiphar affirms its position with science, breaks through with creativity

(GLO)- Not only growing in scale, Binh Dinh Pharmaceutical - Medical Equipment Joint Stock Company (Bidiphar) also made its mark with the emulation movement "Research and application of science and technology, promoting initiatives and technical improvements".

This is not only a slogan but has become the core cultural value of Bidiphar, where every idea is a seed for sustainable development.

In the context of global integration, competition in the pharmaceutical industry is not only in price but also in technology, knowledge content and innovation capacity. Bidiphar has chosen a strategic direction: Turning the emulation movement of scientific research and technical innovation initiatives into core development drivers. The staff to date is nearly 1,400 people, of which more than 600 have university and postgraduate degrees, which are key intellectual resources for research and development (R&D).

Take science as the pillar, competition as the driving force

Bidiphar currently has 15 modern production lines, nearly 400 pharmaceutical products in circulation, 16 branches nationwide and 2 100% owned member companies.

In the period of 2021 - 2024 alone, the Company has nearly 500 initiatives, of which more than 50 important initiatives have brought benefits to Bidiphar of over 10 billion VND/year. These figures not only reflect economic efficiency but also show the strong vitality of the creative emulation movement in the Company.

At the end of 2023, Bidiphar will put into operation a factory producing cancer treatment drugs and start construction of a factory producing small-volume sterile injectable drugs in Nhon Hoi Economic Zone. Photo: MH

According to People's Physician Pham Thi Thanh Huong - General Director of Bidiphar, the Company's leaders launched a broad movement with many synchronous solutions. Along with that, they established an Emulation - Reward Council, built a transparent review regulation; maintained a reward fund and a policy of recognizing initiatives. At the same time, they linked the initiative movement with the direct benefits of employees so that each individual feels responsible and proud when contributing.

“Every idea, no matter how small, that brings practical results, is appreciated, recognized and rewarded. This policy has created a strong spiritual "push", awakening the hidden creative potential in each employee at Bidiphar,” said Ms. Huong.

Bidiphar invests heavily in research and development, averaging 15 - 20 billion VND/year. The R&D Center currently has nearly 100 technical staff, regularly cooperating with the University of Medicine and Pharmacy in Ho Chi Minh City, Hanoi , the Institute of Medicinal Materials, partners from Japan, Europe... On average, each year, 50 new product proposals are researched, 30 - 40 products are commercialized, including many cancer drugs, new generation antibiotics, and artificial kidney dialysis solutions - treatment groups with strategic value.

In particular, the past 5 years have marked Bidiphar's success in research with a series of outstanding scientific topics recognized at the national and provincial levels and having high practical application value. One of the turning points was in 2024, when Bidiphar completed a research and development project and applied technology to produce a number of cancer treatment drugs, including 5 research topics and 1 pilot production project.

“These are “technology passports” that help Bidiphar affirm its No. 1 position in the market share of domestically produced cancer drugs,” Ms. Huong emphasized.

Bidiphar's quality control staff work with cancer treatment products. Photo: DVCC

Another milestone is the research to perfect the production process of Indapamide 1.5 mg and Felodipin 5 mg extended-release tablets, which was recognized by the Ministry of Science and Technology as a national result. Not only saving costs, this project also helps Bidiphar master the slow-release technology, a technique that was previously only applied by major pharmaceutical companies in the world.

Not stopping at chemical drugs, Bidiphar also focuses on local resources. Research on tea, Morinda officinalis, red polygonum multiflorum, and Codonopsis pilosula according to GACP-WHO standards has turned traditional medicinal plants into products that meet international standards. Up to now, the Company has been certified by GACP-WHO for 8 precious medicinal herbs and certified by TCVN 11041 on organic agricultural standards. This is a solid foundation for Bidiphar to build a sustainable raw material area, gradually realizing the circular economic model in the pharmaceutical industry.

Open up new horizons

By 2024, Bidiphar will be in the Top 4 most prestigious pharmaceutical companies in Vietnam, leading in market share of cancer treatment drugs, holding the 2nd position in kidney dialysis solutions. Revenue will reach 1,811 billion VND, pre-tax profit will reach 320 billion VND, budget contribution will reach 100 billion VND, creating jobs for more than 1,000 workers. Average income of workers will reach 10 million VND/month.

The above impressive figures have created Bidiphar's attraction in the international arena. Dominating the market share of domestically produced cancer drugs - a very complex field - has turned this enterprise into a "magnet" attracting the attention of many pharmaceutical corporations in the world. Its strength and leading position in the industry are the most reliable guarantees, paving the way for important negotiations and cooperation agreements.

The movement of scientific research and creative competition has become an endogenous strength, helping Bidiphar maintain the speed of launching 30-40 new products/year, many of which have achieved leading market share immediately after launching. This is the result of a harmonious combination of science - technology - management - people.

Bidiphar's high-tech pharmaceutical factory cluster in Nhon Hoi Economic Zone. Photo: DVCC

However, Ms. Huong also affirmed that today's achievements are just a fulcrum for a long journey ahead. In the vision of the next 3-5 years, Bidiphar sets a clear strategic goal: Top 3 prestigious pharmaceutical manufacturing enterprises in Vietnam, revenue from manufactured products reaching over 3,000 billion VND, maintaining the leading position in the cancer drug market, and expanding exports to Europe and Japan.

Combining digital transformation and modern governance

Another highlight is that Bidiphar proactively combines digital transformation and advanced management such as SAP-ERP system (overall management from finance, human resources, production to logistics), DMS (distribution management, logistics and sales systems), Power BI (data analysis and decision support), Base Workflow (process digitization), internal AI system and KPI (performance measurement, work management). These tools help Bidiphar shorten 30 - 40% of production time, save an average of 20 billion VND/year and create long-term stability for product quality.

In particular, the Company strongly develops R&D with an expected 1.5 - 3% of revenue, launching at least 10 new products each year. In particular, the focus is on biological drugs, new generation cancer drugs, special antibiotics and high-tech products in the form of slow-release tablets. This is not only a product strategy but also demonstrates the step of "shifting from following to mastering" in research...

The aspiration to reach the international market is set by Bidiphar as a key strategic goal. The journey to conquer demanding markets such as Europe, Japan and the ASEAN region will be started with the determination to achieve the most stringent quality standards such as GMP-EU and PIC/S. This is not only a certification goal but also a commitment to product quality globally.

At the same time, promote comprehensive digital transformation through building smart factory models, applying artificial intelligence, internet of things, and big data to optimize from research, production to distribution.

“Bidiphar always upholds the principle of “Tell the truth - do the truth - prove it”. We believe that product quality is the most sustainable competitive advantage. With the spirit of solidarity - creativity - innovation - development, Bidiphar will continue to pioneer in research and application of science and technology, contributing to building a modern, self-reliant and internationally integrated Vietnamese pharmaceutical industry” - General Director Pham Thi Thanh Huong emphasized.

Source: https://baogialai.com.vn/bidiphar-khang-dinh-vi-the-bang-khoa-hoc-but-pha-bang-sang-tao-post567501.html